Download PDF
Semin Thromb Hemost 2008; 34(7): 663-669
DOI: 10.1055/s-0028-1104545
© Thieme Medical Publishers

Von Willebrand Factor: Another Janus-Faced Hemostasis Protein

Massimo Franchini1 , Pier Mannuccio Mannucci2
  • 1Immunohematology and Transfusion Centre, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
  • 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, University of Milan and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
Further Information

Publication History

Publication Date:
15 December 2008 (online)

    Permissions and Reprints

ABSTRACT

von Willebrand factor (VWF) is a multimeric plasma protein that mediates platelet adhesion and aggregation at sites of vascular injury and also acts as a protective carrier of factor VIII. Although the acquired or inherited deficiency of VWF is associated with a bleeding tendency, there is increasing evidence that VWF also plays a pivotal role in thrombosis. The presence in plasma of unusually large VWF multimers, due to the congenital or acquired deficiency of the VWF-cleaving metalloproteinase ADAMTS13, has been implicated in the pathogenesis of thrombotic thrombocytopenic purpura. In addition, high plasma levels of VWF have been associated with an increased risk of atherothrombosis. The current article reviews the literature and provides evidence for the two-faced character that VWF therefore represents.

KEYWORDS

von Willebrand factor - thrombosis - thrombotic thrombocytopenic purpura - coronary artery disease - stroke

REFERENCES

  • 1 Sadler J E. von Willebrand factor: two sides of a coin.  J Thromb Haemost. 2005;  3 1702-1709
    CrossrefPubMedGoogle Scholar
  • 2 Martinelli I. Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis.  Semin Hematol. 2005;  42 49-55
    CrossrefPubMedGoogle Scholar
  • 3 Mannucci P M, Lavoretano S, Peyvandi F. The thrombotic microangiopathies.  Blood Transfus. 2005;  3 120-135
    PubMedGoogle Scholar
  • 4 Castaman G, Federici A B, Rodeghiero F, Mannucci P M. von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.  Haematologica. 2003;  88 94-108
    PubMedGoogle Scholar
  • 5 Sadler J E, Mancuso D J, Randi A M, Tuley E A, Westfield L A. Molecular biology of von Willebrand factor.  Ann N Y Acad Sci. 1991;  614 114-124
    CrossrefPubMedGoogle Scholar
  • 6 Wagner D D. Cell biology of von Willebrand factor.  Annu Rev Cell Biol. 1990;  6 217-246
    CrossrefPubMedGoogle Scholar
  • 7 Ruggeri Z M. Von Willebrand factor.  Curr Opin Hematol. 2003;  10 142-149
    CrossrefPubMedGoogle Scholar
  • 8 Dong J F, Moake J L, Nolasco L et al.. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.  Blood. 2002;  100 4033-4039
    CrossrefPubMedGoogle Scholar
  • 9 Dong J F, Moake J L, Bernardo A et al.. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.  J Biol Chem. 2003;  278 29633-29639
    CrossrefPubMedGoogle Scholar
  • 10 Auton M, Cruz M A, Moake J. Conformational stability and domain unfolding of the Von Willebrand factor A domains.  J Mol Biol. 2007;  366 986-1000
    CrossrefPubMedGoogle Scholar
  • 11 Ruggeri Z M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation.  Best Pract Res Clin Haematol. 2001;  14 257-279
    CrossrefPubMedGoogle Scholar
  • 12 Ruggeri Z M. Von Willebrand factor: looking back and looking forward.  Thromb Haemost. 2007;  98 55-62
    PubMedGoogle Scholar
  • 13 Schmugge M, Rand M L, Freedman J. Platelets and von Willebrand factor.  Transfus Apher Sci. 2003;  28 269-277
    CrossrefPubMedGoogle Scholar
  • 14 Ruggeri Z M. Old concepts and new developments in the study of platelet aggregation.  J Clin Invest. 2000;  105 699-701
    PubMedGoogle Scholar
  • 15 Vlot A J, Koppelman S J, Bouma B N, Sixma J J. Factor VIII and von Willebrand factor.  Thromb Haemost. 1998;  79 456-465
    PubMedGoogle Scholar
  • 16 Tsai H M. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.  J Am Soc Nephrol. 2003;  14 1072-1081
    CrossrefPubMedGoogle Scholar
  • 17 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
    PubMedGoogle Scholar
  • 18 Amorosi E L, Ultmann J E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.  Medicine (Baltimore). 1966;  45 139-159
    CrossrefPubMedGoogle Scholar
  • 19 Rock G A, Shumak K H, Buskard N A et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.  N Engl J Med. 1991;  325 393-397
    CrossrefPubMedGoogle Scholar
  • 20 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
    CrossrefPubMedGoogle Scholar
  • 21 Furlan M, Robles R, Galbusera M et al.. Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
    CrossrefPubMedGoogle Scholar
  • 22 Tsai H M, Chun-Yet Lian E. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
    CrossrefPubMedGoogle Scholar
  • 23 Zheng X, Chung D, Takayama T K et al.. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276 41059-41063
    CrossrefPubMedGoogle Scholar
  • 24 Tsai H M. Molecular mechanisms in thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 2004;  30 549-556
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Upshaw J D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.  N Engl J Med. 1978;  298 1350-1352
    CrossrefPubMedGoogle Scholar
  • 26 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
    CrossrefPubMedGoogle Scholar
  • 27 Klaus C, Plaimauer B, Studt J D et al.. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4514-4519
    CrossrefPubMedGoogle Scholar
  • 28 Scheiflinger F, Knöbl P, Trattner B et al.. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.  Blood. 2003;  102 3241-3243
    CrossrefPubMedGoogle Scholar
  • 29 Rieger M, Mannucci P M, Hovinga J A et al.. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.  Blood. 2005;  106 1262-1267
    CrossrefPubMedGoogle Scholar
  • 30 van der Plas R M, Schiphorst M E, Huizinga E G et al.. Von Willebrand factor proteolysis is deficient in classic but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.  Blood. 1999;  93 3798-3802
    PubMedGoogle Scholar
  • 31 Tsai H M. Current concepts in thrombotic thrombocytopenic purpura.  Annu Rev Med. 2006;  57 419-436
    CrossrefPubMedGoogle Scholar
  • 32 Jeremic M, Weisert O, Gedde-Dahl T W. Factor VIII (AHG) levels in 1016 regular blood donors. The effects of age, sex, and ABO blood groups.  Scand J Clin Lab Invest. 1976;  36 461-466
    CrossrefPubMedGoogle Scholar
  • 33 Gill J C, Endres-Brooks J, Bauer P J, Marks Jr W J, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease.  Blood. 1987;  69 1691-1695
    CrossrefPubMedGoogle Scholar
  • 34 Mannucci P M. von Willebrand factor: a marker of endothelial damage?.  Arterioscler Thromb Vasc Biol. 1998;  18 1359-1362
    PubMedGoogle Scholar
  • 35 Franchini M, Lippi G. The role of von Willebrand factor in hemorrhagic and thrombotic disorders.  Crit Rev Clin Lab Sci. 2007;  44 115-149
    CrossrefPubMedGoogle Scholar
  • 36 Yamashita A, Asada Y, Sugimura H et al.. Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity.  Arterioscler Thromb Vasc Biol. 2003;  23 1105-1110
    CrossrefPubMedGoogle Scholar
  • 37 Meade T W, Cooper J A, Stirling Y et al.. Factor VIII, ABO blood group and the incidence of ischaemic heart disease.  Br J Haematol. 1994;  88 601-607
    CrossrefPubMedGoogle Scholar
  • 38 Folsom A R, Wu K K, Rosamond W D, Sharrett A R, Chambless L E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.  Circulation. 1997;  96 1102-1108
    CrossrefPubMedGoogle Scholar
  • 39 Smith F B, Lee A J, Fowkes F G et al.. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.  Arterioscler Thromb Vasc Biol. 1997;  17 3321-3325
    PubMedGoogle Scholar
  • 40 Rumley A, Lowe G D, Sweetnam P M, Yarnell J W, Ford R P. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study.  Br J Haematol. 1999;  105 110-116
    CrossrefPubMedGoogle Scholar
  • 41 Jager A, van Hinsbergh V W, Kostense P J et al.. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study.  Arterioscler Thromb Vasc Biol. 1999;  19 3071-3078
    CrossrefPubMedGoogle Scholar
  • 42 Morange P E, Simon C, Alessi M C et al.. on behalf of the PRIME study. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study.  Circulation. 2004;  109 1343-1348
    CrossrefPubMedGoogle Scholar
  • 43 Cortellaro M, Boschetti C, Cofrancesco E et al.. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.  Arterioscler Thromb. 1992;  12 1063-1070
    PubMedGoogle Scholar
  • 44 Thompson S G, Kienast J, Pyke S D, Haverkate F, van de Loo J C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.  N Engl J Med. 1995;  332 635-641
    CrossrefPubMedGoogle Scholar
  • 45 Jansson J H, Nilsson T K, von Johnson O. Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.  Heart. 1998;  80 334-337
    PubMedGoogle Scholar
  • 46 Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.  Arterioscler Thromb Vasc Biol. 2000;  20 2019-2023
    PubMedGoogle Scholar
  • 47 Whincup P H, Danesh J, Walker M et al.. von Willebrand factor and coronary heart disease: prospective study and meta-analysis.  Eur Heart J. 2002;  23 1764-1770
    CrossrefPubMedGoogle Scholar
  • 48 Danesh J, Wheeler J G, Hirschfield G M et al.. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.  N Engl J Med. 2004;  350 1387-1397
    CrossrefPubMedGoogle Scholar
  • 49 van der Meer I M, Brouwers G J, Bulk S et al.. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study.  Br J Haematol. 2004;  124 343-347
    CrossrefPubMedGoogle Scholar
  • 50 Franchini M, Lippi G. Von Willebrand factor and thrombosis.  Ann Hematol. 2006;  85 415-423
    CrossrefPubMedGoogle Scholar
  • 51 Folsom A R, Rosamond W D, Shahar E et al.. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.  Circulation. 1999;  100 736-742
    CrossrefPubMedGoogle Scholar
  • 52 Sramek A, Bucciarelli P, Federici A B et al.. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients.  Circulation. 2004;  109 740-744
    CrossrefPubMedGoogle Scholar
  • 53 Spiel A O, Gilbert G C, von Jilma B. Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.  Circulation. 2008;  117 1449-1459
    CrossrefPubMedGoogle Scholar
  • 54 Gilbert J C, DeFeo-Fraulini T, Hutabarat R M et al.. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.  Circulation. 2007;  116 2678-2686
    CrossrefPubMedGoogle Scholar

Massimo FranchiniM.D. 

Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine

University Hospital of Parma, Italy

Email: massimo.franchini@azosp.vr.it

      >